Artemis Therapeutics Inc Share Price OTC Bulletin Board
Equities
US04302Q1094
Biotechnology & Medical Research
Sales 2021 | 0.01 0.55 | Sales 2022 | 0.31 24.45 | Capitalization | 130M 10.22B |
---|---|---|---|---|---|
Net income 2021 | - 0 | Net income 2022 | -1M -78.63M | EV / Sales 2021 * | - |
Net cash position 2021 | 78.02K 6.13M | Net Debt 2022 | 301K 23.67M | EV / Sales 2022 | 418,843,518 x |
P/E ratio 2021 * |
-
| P/E ratio 2022 |
-48.8
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 12.93% |
Managers | Title | Age | Since |
---|---|---|---|
Shimon Citron
CEO | Chief Executive Officer | 70 | 29/06/22 |
David Dana
DFI | Director of Finance/CFO | 60 | 25/07/22 |
Dana Wolf
CTO | Chief Tech/Sci/R&D Officer | 66 | 01/08/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shimon Citron
CEO | Chief Executive Officer | 70 | 29/06/22 |
1st Jan change | Capi. | |
---|---|---|
+17.95% | 125B | |
+13.85% | 108B | |
-7.03% | 23.64B | |
+2.47% | 22.39B | |
-12.11% | 17.78B | |
-41.64% | 16.43B | |
-15.58% | 16.34B | |
+0.29% | 13.56B | |
+24.41% | 11.59B |